BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Pseudomonas infection
,
Kidney
,
Avian flu virus
,
Tamoxifen
,
rs6983267
,
MYC
,
Coagulation
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
als 1
Summary
General Info
Curated Studies
Most Correlated Studies
Gastric cancer AGS cell line treated with 0.01% ornithogalum
Myeloma ALMC1 cells with amyloidosis depleted of immunoglobulin light chain
Clonal plasma cells from bone marrow of amyloidosis subjects
L1000 CMAP - Non-small cell lung cancer HCC515 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Zinc biosorption by Dunaliella sp. AL-1: Mechanism and effects on cell metabolism.
Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5.
Genomic and biological characterization of the novel phages vB_VpaP_AL-1 and vB_VpaS_AL-2 infecting …
Neuroprotective effects of the andrographolide analogue AL-1 in the MPP⁺/MPTP-induced Parkinson's di…
PIWIL1 interacting RNA piR-017061 inhibits pancreatic cancer growth via regulating EFNA5.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS …
CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ